Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®

@article{Zhang2020QualityBD,
  title={Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®},
  author={Erhui Zhang and Liqi Xie and Peilan Qin and L. Lu and Yanpeng Xu and W. Gao and L. Wang and M. H. Xie and Weidong Jiang and S. Liu},
  journal={The AAPS Journal},
  year={2020},
  volume={22}
}
  • Erhui Zhang, Liqi Xie, +7 authors S. Liu
  • Published 2020
  • Mathematics, Medicine
  • The AAPS Journal
  • Quality by design (QbD) is an efficient but challenging approach for the development of biosimilar due to the complex relationship among process, quality, and efficacy. Here, the analytical similarity of adalimumab biosimilar HLX03 to Humira® was successfully established following a QbD quality study. Quality target product profile (QTPP) of HLX03 was first generated according to the public available information and initial characterization of 3 batches of Humira®. The critical quality… CONTINUE READING
    1 Citations

    References

    SHOWING 1-10 OF 40 REFERENCES
    Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
    • 6
    Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
    • 32
    • PDF
    Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
    • 52
    • PDF
    Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach
    • 122
    • Highly Influential
    Determination of critical quality attributes for monoclonal antibodies using quality by design principles.
    • Nadja Alt, T. Zhang, +6 authors R. Harris
    • Computer Science, Medicine
    • Biologicals : journal of the International Association of Biological Standardization
    • 2016
    • 83
    Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
    • 40
    • Highly Influential
    QbD in Biopharmaceutical Manufacturing and Biosimilar Development
    • 1